Advancing HS Outcomes: Resource Prioritization and Success Measurement

A panelist discusses how health system leaders should focus resources on implementing multidisciplinary care teams, standardizing staging/severity assessments, and ensuring access to recommended treatments outlined in current hidradenitis suppurativa (HS) guidelines. Priority areas include early diagnosis through provider education, establishing clear referral pathways to specialists, comprehensive symptom management including pain control, and tracking patient outcomes against quality metrics to improve care delivery and reduce disease burden.

EP: 1.Bridging the Gap in Recognizing Early Symptoms of Hidradenitis Suppurativa

EP: 2.Improving HS Diagnosis and Care Through Better Alignment of Staging and Severity

EP: 3.Addressing Social Determinants of Health in Hidradenitis Suppurativa Care

EP: 4.Economic Implications of Diagnostic Delays in Hidradenitis Suppurativa

EP: 5.Strategies for Equitable Access in Hidradenitis Suppurativa

EP: 6.Partnering With Patient Advocacy Groups to Improve HS Awareness and Outcomes

EP: 7.Holistic Care for HS Patients: The Power of Multidisciplinary Models

EP: 8.The Case for HS Centers of Excellence: Evidence for Improved Patient Outcomes

EP: 9.Innovating HS Care: Applying Multidisciplinary Lessons to Diagnosis and Management

EP: 10.The Value Proposition: Justifying the Investment in HS Centers of Excellence

EP: 11.Key Takeaways on HS Care: Multidisciplinary Collaboration and Equity Solutions

EP: 12.Navigating HS Management: The Patient Journey

Now Viewing

EP: 13.Advancing HS Outcomes: Resource Prioritization and Success Measurement

Video content above is prompted by the following:

• How should health system decision-makers prioritize resources to align with updated guidelines and quality measures?

Related Videos

Related Content

Advertisement

March 20th 2025

Hemoglobin May Protect Against Inflammation From Rheumatoid Arthritis

Brooke McCormick

Regulating hemoglobin levels could help reduce inflammation and improve rheumatoid arthritis management.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 19th 2025

STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children

Christina Mattina

Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 18th 2025

Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic

Christina Mattina

The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.

March 18th 2025

MRI Could Aid in Early Differential Diagnosis of DMD, BMD

Rose McNulty

Multiparametric quantitative MRI could potentially help differentiate between Duchenne muscular dystrophy and Becker muscular dystrophy early and improve the management of these conditions.

Related Content

Advertisement

March 20th 2025

Hemoglobin May Protect Against Inflammation From Rheumatoid Arthritis

Brooke McCormick

Regulating hemoglobin levels could help reduce inflammation and improve rheumatoid arthritis management.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

March 19th 2025

STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children

Christina Mattina

Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

March 18th 2025

Bustling Gene Therapy Pipeline for Neuromuscular Diseases Brings Thorny Questions to the Clinic

Christina Mattina

The rapid development of gene therapy options for treating neuromuscular diseases has created new therapeutic options but also logistical hurdles and a need for complex discussions between clinicians and families.

March 18th 2025

MRI Could Aid in Early Differential Diagnosis of DMD, BMD

Rose McNulty

Multiparametric quantitative MRI could potentially help differentiate between Duchenne muscular dystrophy and Becker muscular dystrophy early and improve the management of these conditions.